NCT05305677Completed
Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome
Effect of NMN (Nicotinamide Mononucleotide) Intervention on Patients With Polycystic Ovary Syndrome
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
The purpose of the study is to understand the effect of Nicotinamide mononucleotide (NMN) on patients with polycystic ovary syndrome.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 88 (actual)
- First submitted
- 14 Mar 2022
- Start date
- 1 Jun 2022
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Peking University Third Hospital
- NCT number
- NCT05305677
What you commit to
- Study type: Interventional
- Participants enrolled: 88
- From 1 Jun 2022 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals who currently receiving weight-loss drugs or surgery or within the past 2 months.
- Use of medications that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 2 months.
Other illness
- Individuals who suffering from other diseases that may cause hyperandrogenism and ovulation abnormalities.
- Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.
- Individuals with severe liver diseases or kidney disease that are ineligible to participate in the study.
- A medical history of severe cardiovascular and cerebrovascular diseases.
- Individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption.
- Individuals who need drug treatment for any mental illness such as epilepsy and depression.
- Cancer patients.
- Individuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc.
Other
- Individuals who are during pregnant, lactation or menopause.
- Individuals who take niacin, nicotinamide, or other vitamin B-related supplementation currently or within the past 2 months.
- Individuals who drink more than 15g of alcohol per day or have a smoking habit.
Who the study is looking for
- Individuals who are 20 to 40 years old;
- BMI \< 25 kg/m2;
- Individuals with PCOS should meet all the Rotterdam diagnostic criteria: 1) Oligo- and/or anovulation; 2) Clinical and/or biochemical signs of hyperandrogenism; 3) Polycystic ovaries, and exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome).
- Individuals who can insist on continuous monitoring in the outpatient clinic.
- Individuals who are not participating in other research projects currently or 3 months before the intervention.
Age in the registry: 20 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Third Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.